Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

10 Feb 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Genomic Health fourth quarter total revenue increases to $60.4 million

Genomic Health, Inc. today reported financial results and business progress for the quarter and year ended December 31, 2012.

6 Feb 2013

Surgery could boost chemotherapy outcomes in canine TCC

Dogs that undergo curative surgery for transitional cell carcinoma before initiating a combination of doxorubicin and piroxicam therapy have significantly longer median overall survival than their counterparts not pretreated surgically, report researchers.

6 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Previously poorly investigated signalling pathway crucial for proliferation of prostate cancer cells

A previously poorly investigated signalling pathway is crucial for the growth and proliferation of prostate cancer cells. An international research team discovered this when studying the enzyme "soluble adenylyl cyclase" that produces the second messenger molecule cAMP.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Subclinical hypothyroidism not prognostic in thyroid carcinoma

Subclinical hypothyroidism is not an independent predictor for clinical outcomes in patients with papillary thyroid carcinoma, research shows.

5 Feb 2013

Interferon retreatment warning in HCV

Hepatitis C virus patients who do not respond to interferon should not receive further treatment with the drug, say the authors of a new Cochrane review.

4 Feb 2013

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

HIV-positive patients have higher incidence of non-melanoma skin cancers

HIV-positive patients have a higher incidence of non-melanoma skin cancers, according to a Kaiser Permanente study that appears in the current online issue of the Journal of the National Cancer Institute. Specifically, basal cell and squamous cell carcinomas occur more than twice as often among HIV-positive individuals compared to those who are HIV-negative.

30 Jan 2013

Five genes hold key to meningioma make up

Research published in Science shows that mutations in five genes characterize most meningiomas.

28 Jan 2013

Shorter surveillance intervals detect HCC earlier

Hepatocellular carcinoma surveillance in at-risk patients at intervals of less than 6 months picks up smaller tumors compared with longer intervals, show two recently published studies.

28 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 will be presented in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.

23 Jan 2013

MRI ‘good accuracy’ for detecting residual breast cancer

Magnetic resonance imaging is superior to mammography for the detection of residual breast cancer after neoadjuvant chemotherapy, research confirms.

21 Jan 2013

Scientists identify new mechanism for schistosomiasis-bladder cancer connection

About 200 million people across 75 of the poorest countries in the world are now infected by the blood parasite Schistosoma haematobium (S. haematobium). The infection causes severe urogenital disease, but also causes bladder cancer in a number of patients and why this occurs is not clear.

17 Jan 2013

Human papillomavirus an etiologic factor in 6% of OCSCC cases

High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.

14 Jan 2013